Show results for
Refine by
Metabolic Control Articles & Analysis
2 news found
With two-year follow-up from 34 patients in the per-protocol (PP) population, the study observed no long-term adverse events from Revita in patients with poorly controlled diabetes on oral glucose-lowering medications. In the cohort followed through two years, HbA1c was observed to be statistically significantly reduced at all time points, as were broader measures of ...
“The Revita T2Di pivotal study addresses a significant challenge in today's treatment of type 2 diabetes, which is that most patients on insulin are still not able to achieve adequate glycemic (blood sugar) control. There is increasing evidence for the role of the gut in metabolic diseases, and data from earlier clinical studies of Revita DMR is ...